Wu X - Search Results

1

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.

Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC. Hawse JR, et al. Among authors: wu x. PLoS One. 2013;8(1):e54613. doi: 10.1371/journal.pone.0054613. Epub 2013 Jan 28. PLoS One. 2013. PMID: 23382923 Free PMC article.

2

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. Wu X, et al. Cancer Res. 2009 Mar 1;69(5):1722-7. doi: 10.1158/0008-5472.CAN-08-3933. Epub 2009 Feb 24. Cancer Res. 2009. PMID: 19244106

3

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.

Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Wu X, et al. Breast Cancer Res. 2011 Mar 10;13(2):R27. doi: 10.1186/bcr2844. Breast Cancer Res. 2011. PMID: 21392396 Free PMC article.

4

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.

Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Wu X, et al. J Cell Biochem. 2012 Feb;113(2):711-23. doi: 10.1002/jcb.23443. J Cell Biochem. 2012. PMID: 22095450 Free PMC article.

5

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR. Reese JM, et al. Among authors: wu x. BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749. BMC Cancer. 2014. PMID: 25288324 Free PMC article.

6

Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors.

Winters JL, Davila JI, McDonald AM, Nair AA, Fadra N, Wehrs RN, Thomas BC, Balcom JR, Jin L, Wu X, Voss JS, Klee EW, Oliver GR, Graham RP, Neff JL, Rumilla KM, Aypar U, Kipp BR, Jenkins RB, Jen J, Halling KC. Winters JL, et al. Among authors: wu x. J Mol Diagn. 2018 Jul;20(4):495-511. doi: 10.1016/j.jmoldx.2018.03.007. Epub 2018 Jun 19. J Mol Diagn. 2018. PMID: 29929942 Free article.

7

MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.

Lou Z, Minter-Dykhouse K, Wu X, Chen J. Lou Z, et al. Among authors: wu x. Nature. 2003 Feb 27;421(6926):957-61. doi: 10.1038/nature01447. Nature. 2003. PMID: 12607004

8

Characterization of CHEK2 mutations in prostate cancer.

Wu X, Dong X, Liu W, Chen J. Wu X, et al. Hum Mutat. 2006 Aug;27(8):742-7. doi: 10.1002/humu.20321. Hum Mutat. 2006. PMID: 16835864

9

A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival.

Yamane K, Wu X, Chen J. Yamane K, et al. Among authors: wu x. Mol Cell Biol. 2002 Jan;22(2):555-66. doi: 10.1128/MCB.22.2.555-566.2002. Mol Cell Biol. 2002. PMID: 11756551 Free PMC article.

10

Impact of RNA degradation on fusion detection by RNA-seq.

Davila JI, Fadra NM, Wang X, McDonald AM, Nair AA, Crusan BR, Wu X, Blommel JH, Jen J, Rumilla KM, Jenkins RB, Aypar U, Klee EW, Kipp BR, Halling KC. Davila JI, et al. Among authors: wu x. BMC Genomics. 2016 Oct 20;17(1):814. doi: 10.1186/s12864-016-3161-9. BMC Genomics. 2016. PMID: 27765019 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54,392 results

Search Page